Novel approaches that promote lung endothelial and epithelial repair and anti pro inflammatory cytokines could be a future promising agent in the management of ARDS
The acute respiratory distress syndrome (ARDS) is a common cause of respiratory failure in critically ill patients and is defined by the acute onset of noncardiogenic pulmonary edema, hypoxemia, and the need for mechanical ventilation. ARDS occurs most often in the setting of pneumonia, sepsis, aspi...
Main Authors: | Montaser Alrjoob, Alaa Alkhatib, Rana Padappayil, Husam Bader, Doantrang Du, Chandler Patton |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-12-01
|
Series: | Clinical Immunology Communications |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2772613423000239 |
Similar Items
-
Distinct temporal characteristics of circulating alveolar epithelial and endothelial injury markers in ARDS with COVID-19
by: Kentaro Tojo, et al.
Published: (2021-05-01) -
Promises and challenges of personalized medicine to guide ARDS therapy
by: Katherine D. Wick, et al.
Published: (2021-11-01) -
Progress in cytokine research for ARDS: A comprehensive review
by: Zhou Kaihuan, et al.
Published: (2024-10-01) -
Alveolar cytokines and interferon autoantibodies in COVID-19 ARDS
by: Trine B. Jonassen, et al.
Published: (2024-03-01) -
Endothelial biomarkers in human sepsis: pathogenesis and prognosis for ARDS
by: Carolyn M. Hendrickson, et al.
Published: (2018-04-01)